Hydroxychloroquine UPSC | Hydroxychloroquine For Covid-19 – Ministry of Health and Family Welfare declared the Hydroxycholoroquine as a Schedule H1 drug. With this GOI has brough upon restrictions on sales and Export Of This Drug . But Now It is again In Demand After USA President Donald Trump Asked For India help In Import Of  Hydroxychloroquine For Covid-19 Patient Treatment .

Earlier WHO Suggests Four Measures For treatment Of Covid 19 Patients . All Four Measures List Are Given Below .

Hydroxychloroquine UPSC | Hydroxychloroquine For Covid-19

Hydroxychloroquine UPSC | Hydroxychloroquine For Covid-19

The WHO is testing four most promising treatments to combat the virus. It includes 

  • Remdesivir, an anti-viral compound
  • Chloroquine and Hydroxychloroquine, the Malarial medications
  • Combination of Lopinavir and Ritonavir, HIV drugs
  • Interferon-beta along with the combination of Lopinavir and Ritonavir


  • Hydroxychloroquine is an antimalarial drug that is also used for treating rheumatoid arthritis.
  • The ICMR’s approval followed a recommendation from its task force for COVID-19.
  • The clarification comes as none of the drug approving agencies across the world, including the FDA, has cleared the drug for prophylaxis or for treating COVID-19 patients.

What is Schedule H1 Drugs ?

The drugs listed under Schedule H1 are required to be sold under following conditions

  • The supply if H1 drugs are to be registered in a separate register.
  • The register should hold the name and address of the prescriber and the patient.
  • It should also hold quantity supplied. And these details are to be held by the supplier for a minimum of three
  • The drug listed under Schedule H1 should be labelled as “Rx” in red colour.
  • The label should also carry precautionary warnings.

What does ICMR Say About This Drug ?

  • The National Task Force COVID-19 constituted by Indian Council of Medical Research (ICMR) on 23rd March, recommended the use of hydroxy-chloroquine for the treatment of COVID-19 for high-risk cases.
  • The Drug Controller General of India (DCGI) has also approved the protocol recommended by the ICMR National Task Force for limited use in crisis situation.